Ropinirole in Gilles de la Tourette syndrome.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15136698.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effects of treatment with ropinirole (0.25 to 0.5 mg bid) were examined using an open-label design for 8 weeks in 15 subjects with Gilles de la Tourette syndrome (GdlT). All patients completed the study, and most showed an improvement in their tics during treatment. Low-dose ropinirole may improve the motor features in GdlT, but further controlled studies are necessary.
Medical subject headings
- Dopamine Agonists
- Indoles
- Tourette Syndrome